Managing the IBD Patient: Change in Diagnosis – Transformation from UC to Crohn’s Disease

Managing the IBD Patient: Change in Diagnosis – Transformation from UC to Crohn’s Disease is organized by Integrity Continuing Education Inc.

Target Audience:
This educational initiative has been designed for all members involved in the IBD-care continuum. Of those that will derive the most benefit from this program are gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician’s assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

Accreditation:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Overview:
Inflammatory Bowel Diseases (IBD), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic, disabling, and progressive diseases of the gastrointestinal tract. For several decades, patients with IBD were limited to therapies that provided symptom relief but did not change the disease course. Despite an increased understanding of IBD pathophysiology and the introduction of corresponding targeted treatments with the potential to alter the disease’s natural history, clinical and endoscopic remission remain elusive for many patients. In order to effectively treat IBD, gastroenterologists and the multidisciplinary IBD team of clinicians need strong foundational knowledge of the broad range of therapeutic agents licensed for the induction and maintenance of disease control, and how to individualize their use for any given patient. Education is necessary to ensure that clinicians who manage patients with IBD are up-to-date on current management strategies, including the use of objective measures such as mucosal healing and deep remission; new and emerging therapies, particularly novel mechanisms of action and safety profiles; and recent data from clinical trials. Clinicians must be knowledgeable regarding the benefits of early intervention, top-down versus step-up approaches, strategies for attaining remission and reducing healthcare costs, and new treat-to-target recommendations for management. Communication about these myriad challenges is essential for improved treatment of IBD, yet opportunities to participate in meaningful peer-to-peer discussion, engage interdisciplinary colleagues, encourage debate, and truly listen to patients are increasingly limited in today’s healthcare environment. @MondayNightIBD strives to reduce these gaps by developing a conversational style venue that fosters deeper educational impact and ultimately improves patient care.

Learning Objectives:
Upon completion of this educational activity, participants will be able to:
• Outline current approaches and guideline-directed strategies for the management of IBD
• Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD
• Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD